Dabaco Group Company (Dabaco) has been granted the license to market the ASF vaccine as of February 28, 2025, following nearly five years of research.
The Dacovac-ASF2 vaccine is the result of a collaborative effort between the USDA and Vietnam’s Ministry of Agriculture and Environment, and it has been transferred to Dabaco for manufacturing since 2020.
In 2024, Dabaco formed a cooperation agreement with Guangdong Winsun Bio Pharmaceutical from China and Cuba’s Labiofam Entrepreneurial Group, both of which are major producers of biological products. This collaboration aims to enhance the research and production of veterinary vaccines. However, the specific roles of these two partners in the production of the Dacovac-ASF2 vaccine have not yet been clearly mentioned by Dabaco.
The company has established the Dacovet vaccine factory in Bac Ninh City, which features a production capacity of 200 million doses per year. In addition to the Dacovac-ASF2 vaccine, the Dacovet factory will also produce vaccines for PRRS and FMD—two of the most serious diseases that commonly affect Vietnam’s pig populations.
Dabaco is set to boost its investment in a variety of projects aimed at expanding its pig production portfolio. These initiatives will include the establishment of five breeding farms and commercial farming complexes, with a total projected investment exceeding USD 110 million over the 2024-2028 period.
The investment plan also encompasses the development of a feedmill, an industrial cluster in Bac Ninh, and a research and development center linked to the vaccine production plant, with an estimated investment of over USD 93 million.
Dabaco has set an ambitious goal to increase its revenue by 1.5 times in 2024, targeting around USD 1.4 to 1.5 billion, while aiming for an average profit growth of at least 7% each year.
pigtalks.asia 
Leave a comment